A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Verastem, Inc.
Eli Lilly and Company
Eli Lilly and Company
Astellas Pharma Inc
AstraZeneca
Incyte Corporation
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Novartis
Eikon Therapeutics
AstraZeneca
BeiGene
BioAtla, Inc.
Checkpoint Therapeutics, Inc.
Phanes Therapeutics
Genentech, Inc.
Jiangsu Hansoh Pharmaceutical Co., Ltd.
Nektar Therapeutics
Eli Lilly and Company
NextCure, Inc.
AbbVie
Mereo BioPharma
Eli Lilly and Company
AbbVie
Clovis Oncology, Inc.
AstraZeneca
CanBas Co. Ltd.
Millennium Pharmaceuticals, Inc.
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company